Provectus Biopharmaceuticals announces license agreement with University of Miami
March 28, 2024Business Services License Agreement, Opthalmology, Provectus Biopharmaceuticals, University of Miami
Provectus Biopharmaceuticals has announced that it has entered into an exclusive worldwide license agreement with the University of Miami, US …
FDA approves Merck’s Winrevair for PAH treatment
March 27, 2024Medical Communications Cardiology, FDA, Merck, Winrevair, pulmonary arterial hypertension
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
Heidelberg Pharma gains FDA ODD for ATAC candidate
March 27, 2024Research and Development FDA, Oncology, heidelberg pharma, multiple myeloma
Heidelberg Pharma has announced that it has gained Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
March 26, 2024Research and Development Cancer, Curve Therapeutics, HIF inhibition, Oncology, oncology
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research in the Journal of the …
AbbVie to acquire Landos Biopharma for approximately $137.5m
March 26, 2024Business Services AbbVie, Landos Biopharma, Pharmacy, acquisition
AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under which AbbVie will acquire Landos …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
March 25, 2024Medical Communications AstraZeneca, FDA, Neurology, Ultomiris, neuromyelitis optica spectrum disorder
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) as the first and only …
FDA approves J&J’s Opsynvi for PAH treatment
March 25, 2024Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …
FDA approves Idorsia’s Tryvio for treatment of high blood pressure
March 22, 2024Medical Communications Cardiology, FDA, Tryvio, blood pressure, blood presure, hypertension
Idorsia has announced that the US Food and Drug Administration (FDA) has approved Tryvio (aprocitentan) for the treatment of hypertension …
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
March 22, 2024Medical Communications CHMP, Diabetes, Novo Nordisk, diabetes
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended …
MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment
March 21, 2024Medical Communications Hyqvia, MHRA, Neurology, Takeda, chronic inflammatory demyelinating polyneuropathy
Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to Hyqvia as a …
Sosei Heptares doses first patient in trial for inflammatory bowel disease treatment
March 21, 2024Research and Development Gastrointestinal tract, Sosei Heptares, clinical trial, inflammatory bowel disease, phase 1 trial
Sosei Heptares has announced that it has dosed the first patient in its phase 1 trial assessing a novel EP4 …
Boehringer Ingelheim’s Spevigo gains additional approvals in US and China
March 20, 2024Medical Communications Boehringer Ingelheim, Dermatology, FDA, Spevigo, psoriasis
Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and Drug Administration (FDA) for the …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
March 20, 2024Manufacturing and Production Lonza, Pharmacy, Roche, biologics, facility, manufacturing
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics site based in Vacaville, California, …
J&J MedTech to work with NVIDIA for surgical AI
March 19, 2024Research and Development Johnson & Johnson MedTech, NVIDIA, Pharmacy, surgery, surgical AI
Johnson & Johnson (J&J) MedTech has announced that it is working in collaboration with NVIDIA to accelerate and scale artificial …
AstraZeneca to acquire Fusion for approximately $2bn
March 19, 2024Business Services AstraZeneca, Fusion Pharmaceuticals, Oncology, acquisition, radioconjugates
AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn. This …
GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment
March 18, 2024Research and Development GSK, Jemperli, Oncology, clinical trial, endometrial cancer, women's health
GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) …
Merck shares results for Keytruda in cervical cancer treatment
March 18, 2024Research and Development Merck, Oncology, cervical cancer, keytruda, women's health
Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-A18 trial, …
Allumiqs and Prolytix enter partnership for acceleration of drug discovery and development
March 15, 2024Research and Development Allumiqs, Pharmacy, drug discovery, partnership
Allumiqs and Prolytix have announced that they have entered into a long-term, strategic partnership with the aim of providing collaboratinve …
FDA approves first treatment for liver scarring due to fatty liver disease
March 15, 2024Medical Communications Endocrinology, FDA, fatty liver disease, liver scarring, nash
The US Food and Drug Administration (FDA) has announced that it has approved Rezdiffra (resmetirom) for the treatment of adult …
AstraZeneca to acquire Amolyt Pharma for up to $1.05bn
March 14, 2024Business Services Amolyt Pharma, AstraZeneca, Rare Diseases, acquisition, rare diseases
AstraZeneca has announced that it has entered into a definitive agreement under which it will acquire Amolyt Pharma for up …
Latest content
FibroFind appoints Lee Borthwick as CEO
